
HSBC Stock: What's New?
HSBC UK, Sheffield (Photo by Mike Egerton/PA Images via Getty Images)
HSBC's stock (NYSE: HSBC) has performed quite well this year, increasing by approximately 21% since the beginning of January. In comparison, its competitor JP Morgan (NYSE: JPM) is only up about 10% during the same timeframe. So, what's going on with HSBC stock?
HSBC's financials have remained fairly strong. The major banking institution announced earnings for Q1 2025 that exceeded expectations. Although revenues fell 15% from last year, down to $17.65 billion, mainly due to business disposals in Canada and Argentina, profits before tax were $9.48 billion, representing a 25% decrease compared to the previous year; however, these results significantly surpassed forecasts. Profit before tax increased by nearly 317% from the previous quarter, indicating strong sequential growth. Strong performances in the Wealth business, Foreign Exchange, and Debt and Equity Markets have fueled profits and revenue in recent quarters. Incidentally, market leadership is indeed one of the factors we evaluate in constructing the market-beating Trefis High Quality portfolio (HQ) – a strategy encompassing 30 stocks aiming for long-term value creation. HQ has outperformed the S&P 500 and generated returns exceeding 91% since its inception. Separately, see – Should You Buy CRWV Stock After A Whopping 4x Rise?
HSBC is increasingly depending on fee-based products in areas like its Wealth and Personal Banking division to fuel growth. Revenue for the Wealth business rose 21% year-over-year during Q1, driven by robust client acquisition and activity in Asia, especially in Hong Kong and India. HSBC has been placing greater emphasis on affluent clients in Asia, with its Hong Kong operations witnessing a 29% sequential increase in new customers.
The Global Private Banking segment is also performing well, supported by strong brokerage and trading activity in Asia. HSBC is introducing new wealth products and promotional offers, including cash incentives for new inflows, to attract and retain premium clients. Asset management revenues have been boosted by increasing assets under management, favorable market trends, and heightened life insurance-related earnings. The current fluctuations in the stock markets are anticipated to benefit the wealth business to some degree, as individuals increasingly pursue advisory services, while brokerage and trading sectors are also expected to gain.
The banking giant warned that loan demand and credit quality might face challenges in the future due to the wider effects of U.S. President Donald Trump's tariffs on major trading partners. Although the earnings have not yet fully incorporated the entire impact of the recently instated reciprocal tariffs, HSBC is primarily a trade-oriented bank when compared to its peers. In its earnings call held in late April, HSBC indicated that it was experiencing a significant decline in transaction volumes along the U.S.-China corridor for sectors not exempt from tariffs. The bank mentioned that an economic slowdown could result in a low single-digit effect on its revenues for the fiscal year, while facing up to $500 million in additional anticipated credit losses. Nonetheless, developments in U.S.-China trade negotiations in recent weeks have sparked some optimism for reducing tensions.
There are a few reasons for optimism regarding HSBC stock. Firstly, its valuation is still considered fair, as the stock is trading at just over 1x tangible book value (net assets minus goodwill). The bank is also concentrating on enhancing efficiency and reducing costs, with a target of annualized savings of $1.5 billion by the end of the next year. In January, HSBC outlined its plans to scale back its mergers and acquisitions as well as some equities businesses in Europe and the Americas, while refocusing on its more profitable markets in Asia, which are seeing quicker economic growth, increasing wealth, and availability of more low-cost deposits. HSBC is also amplifying its commitment to capital returns, having recently increased its share repurchase authorization to $3 billion, with the new buyback anticipated to be completed before its 2025 interim results.
This could also help bolster the stock price. Furthermore, the bank aims for a mid-teens return on average tangible equity between 2025 and 2027, which is above the average for the industry. On the flip side, HSBC's core net interest income (NII) might be under pressure due to declining interest rates, creating a challenge for overall revenue growth, as net interest income accounts for around half of the bank's total revenue. For more information, see our analysis concerning HSBC's valuation for a closer look at what's driving our valuation for HSBC stock.
While HSBC may offer steady growth, the Trefis HQ portfolio is concentrated on long-term value creation. With a collection of 30 stocks, it has a track record of successfully outperforming the S&P 500 over the past four years. What's the reason? As a group, HQ Portfolio stocks have provided better returns with reduced risk compared to the benchmark; offering a calmer experience akin to HQ Portfolio performance metrics.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting. 'The results of our Phase 1b ARGX-119 study in congenital myasthenic syndromes, an ultra-rare disorder that affects patients from birth, builds on our experience and understanding of myasthenic disorders and aligns with our aspiration to serve even more patients living with these debilitating diseases,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. 'ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of our innovation model where our deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what's possible. argenx remains focused on uncovering new biological insights into misunderstood diseases to meaningfully change the lives of patients who have long-been underserved,' said Peter Ulrichts, Ph.D., Chief Scientific Officer of argenx. The decision to advance the development of ARGX-119 in CMS is supported by the results of the Phase 1b study. ARGX-119 demonstrated a favorable safety and tolerability profile, which was the primary endpoint. Efficacy was evaluated across multiple secondary and exploratory endpoints, including Six-Minute Walk Test (6MWT), Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Consistent improvements were observed in treated DOK7-CMS patients through the 12-week study across multiple efficacy scores. Phase 1b CMS Study Design The Phase 1b, multicenter, randomized, double-blinded, placebo-controlled clinical trial assessed safety, tolerability, PK, immunogenicity, and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. The study was also designed to demonstrate proof-of-biology through preliminary efficacy assessments, including muscle weakness, fatigability, daily activities and patient-reported global health outcomes. The clinical trial spanned approximately 11 months across a screening period (up to 28 days), a 12-week treatment period and a follow-up period of nearly seven months. At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo. The primary objective was to evaluate safety and tolerability; secondary objectives included PK, immunogenicity and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. All but one of the patients enrolled in the Phase 1b study also participated in an observational natural history study initiated by argenx in 2024 to better understand the CMS patient journey and disease burden, helping to inform future development plans. About Congenital Myasthenic Syndromes Congenital Myasthenic Syndromes (CMS) are an ultra-rare and heterogenous group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of the neuromuscular junction. Early age of onset and fatigable muscle weakness are considered clinical hallmarks of CMS. Muscle weakness can be debilitating and life-threatening causing difficulties in speaking or swallowing, impaired or absent mobility, proximal arm and leg weakness, and respiratory insufficiency. DOK7 variations are one of the more frequent and severe causes of CMS, accounting for approximately 24% of CMS cases. There are no approved treatments. The prevalence of CMS is estimated to be 5 per 1M (DOK7-CMS estimated to be 1.2 per 1M). About ARGX-119 ARGX-119 is a first-in-class humanized agonist monoclonal antibody (mAb) that specifically targets and activates muscle-specific tyrosine kinase (MuSK) to promote maturation and stabilization of the neuromuscular junction (NMJ). It is a mAb derived from llamas and discovered using the argenx SIMPLE Antibody™ platform technology. ARGX-119 is being developed for patients with neuromuscular disease, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). ARGX-119 was developed through argenx's IIP program in collaboration with the world's leading key opinion leaders on MuSK and the NMJ, Professor Steven J. Burden from MGH, Professor Shohei Koide from NYU and Professor Jan Verschuuren and Associate Professor Maartje Huijbers from LUMC. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Media: Colin McBeancmcbean@ Investors: Alexandra Roy aroy@ Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aims,' 'committed,' or 'plan' and include statements argenx makes concerning its commitment to improving the lives of people suffering from severe autoimmune diseases; its plan to advance the clinical development of ARGX-119 to a registrational study in CMS patients; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
39 minutes ago
- Bloomberg
Norway Pension Fund Blacklists Firms Supplying Israeli Military
Norway's largest private pension fund has excluded two defense companies from its portfolio, citing their ties to the Israeli military and the war in Gaza. KLP Pension, which oversees about $114 billion, said in a statement on Monday that it won't invest in Oshkosh Corp. or ThyssenKrupp AG because they sell weapons to the Israeli military.

Yahoo
an hour ago
- Yahoo
Cannes is done with huge cruise ships. The French city is joining the overtourism backlash
PARIS (AP) — The French Riviera resort of Cannes is imposing what its city council calls 'drastic regulation' on cruise ships, banning any vessels carrying more than 1,000 people from its harbor starting next year. The home of the world's premier film festival is joining a growing global backlash against overtourism, which recently saw uproar over Jeff Bezos' and Lauren Sanchez' Venice wedding this weekend, water-gun protests in Spain and a surprise strike at the Louvre Museum. 'Less numerous, less big, less polluting and more esthetic' — that's the aim of Cannes city councilors who voted Friday to introduce new limits on cruise ships in its ports starting Jan. 1. Only ships with fewer than 1,000 passengers will be allowed in the port, with a maximum of 6,000 passengers disembarking per day. Larger ships will be expected to transfer passengers to smaller boats to enter Cannes. France — which drew in some 100 million visitors last year, more than any other European country and more than the country's population — is on the front line of efforts to balance economic benefits of tourism with environmental concerns while managing ever-growing crowds. 'Cannes has become a major cruise ship destination, with real economic benefits. It's not about banning cruise ships, but about regulating, organizing, setting guidelines for their navigation,' Mayor David Lisnard said in a statement. Cruise operators have called such restrictions damaging for destinations and for passengers. Two cruise ships were scheduled to dock in Cannes on Sunday, each bigger than the upcoming 1,000-passenger limit and with a combined capacity of more than 7,000 people. Their owners did not immediately respond to requests for comment on the new restrictions. The nearby Mediterranean city of Nice announced limits on cruise ships earlier this year, as have some other European cities.